Koudeke, Netherlands

Gijsbertus Johannes Ziere



 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 49(Granted Patents)


Location History:

  • Koudekerk Aan Den Rijn, NL (2011)
  • Koudeke, NL (2013 - 2015)

Company Filing History:


Years Active: 2011-2015

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Gijsbertus Johannes Ziere: Innovator in Ischemia-Reperfusion Injury Treatment

Introduction

Gijsbertus Johannes Ziere is a notable inventor based in Koudeke, Netherlands. He has made significant contributions to the field of medical therapeutics, particularly in the treatment of ischemia-reperfusion injuries. With a total of three patents to his name, Ziere's work is recognized for its potential impact on patient care.

Latest Patents

Ziere's latest patents focus on the use of C1 inhibitor for the prevention of ischemia-reperfusion injury. The invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing, and treating ischemia and reperfusion injury. Notably, the C1 inhibitor remains therapeutically effective even when administered after an ischemic period and reperfusion. This characteristic makes it particularly useful for unforeseen occurrences of ischemic reperfusion, such as strokes.

Career Highlights

Gijsbertus Johannes Ziere is associated with Pharming Intellectual Property Bv, where he continues to develop innovative solutions in the medical field. His work has garnered attention for its potential to improve outcomes for patients suffering from ischemic conditions.

Collaborations

Ziere has collaborated with notable colleagues, including Maurice Mannesse and Johannes Henricus Nuijens. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Gijsbertus Johannes Ziere is a prominent inventor whose work in ischemia-reperfusion injury treatment showcases the importance of innovation in medicine. His contributions through patents and collaborations highlight the potential for improved therapeutic options in critical health situations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…